Literature DB >> 22398650

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.

Rodrigo E Mendes1, Athanassios Tsakris, Helio S Sader, Ronald N Jones, Donald Biek, Pamela McGhee, Peter C Appelbaum, Klaudia Kosowska-Shick.   

Abstract

OBJECTIVES: To characterize the mechanisms responsible for elevated MICs of ceftaroline for methicillin-resistant Staphylococcus aureus (MRSA).
METHODS: During the 2008 Assessing Worldwide Antimicrobial Resistance Evaluation ('AWARE') surveillance programme, four S. aureus collected from separate patients in Athens, Greece, demonstrated ceftaroline MICs of 4 mg/L. These isolates were clonally related and one strain (13101) was selected for further characterization. Two strains (4981 and 4977) displaying ceftaroline MICs of 1 and 2 mg/L, respectively, were included for comparison. All strains originated from the same hospital. Penicillin-binding protein (PBP) affinities for ceftaroline and comparators were determined. Strains were typed by single-locus typing (i.e. spa typing), multilocus sequence typing ('MLST') and by multiple-locus variable-number tandem repeat fingerprinting (MLVF). The presence of Pantone-Valentine leucocidin and the staphylococcal cassette chromosome mec types was assessed. We also performed nucleotide sequencing of the mecA (encoding PBP2a) promoter and ribosomal binding site (rbs) regions and mecR1.
RESULTS: Ceftaroline demonstrated the highest PBP2a affinity with strain 4981 (ST5-MRSA-II) (IC(50) 0.06 mg/L; MIC 1 mg/L). Strains 4977 and 13101 (both ST239-MRSA-III) showed indistinguishable MLVF profiles. Ceftaroline PBP2a binding affinity in strains 4977 (IC(50) 0.25 mg/L; MIC 2 mg/L) and 13101 (IC(50) 1 mg/L; MIC 4 mg/L) was 4- and 16-fold lower than 4981, respectively. Strain 4981 contains a wild-type PBP2a, while strains 4977 and 13101 have N(146)K and E(150)K alterations in the non-penicillin-binding domain. Additionally, 13101 has one substitution (H(351)N) in the transpeptidase domain. Alterations in the mecR1, mecA promoter or rbs regions were not observed.
CONCLUSIONS: Increased ceftaroline MICs were associated with decreased PBP2a binding affinity and reflected alterations in PBP2a.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398650     DOI: 10.1093/jac/dks069

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  35 in total

Review 1.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

2.  PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  S Wesley Long; Randall J Olsen; Shrenik C Mehta; Timothy Palzkill; Patricia L Cernoch; Katherine K Perez; William L Musick; Adriana E Rosato; James M Musser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function.

Authors:  Lisandro H Otero; Alzoray Rojas-Altuve; Leticia I Llarrull; Cesar Carrasco-López; Malika Kumarasiri; Elena Lastochkin; Jennifer Fishovitz; Matthew Dawley; Dusan Hesek; Mijoon Lee; Jarrod W Johnson; Jed F Fisher; Mayland Chang; Shahriar Mobashery; Juan A Hermoso
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-01       Impact factor: 11.205

4.  Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.

Authors:  Regina Fernandez; Liliana I Paz; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

5.  Ceftaroline Activity against mecC-Containing Staphylococcus aureus.

Authors:  Sushmita D Lahiri; Richard A Alm
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

6.  Ceftaroline-heteroresistant Staphylococcus aureus.

Authors:  Stephanie N Saravolatz; Hayley Martin; Joan Pawlak; Leonard B Johnson; Louis D Saravolatz
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

Review 7.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

8.  In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.

Authors:  Jeshina Janardhanan; Jayda E Meisel; Derong Ding; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

9.  Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter.

Authors:  Wonhee So; Jared L Crandon; George G Zhanel; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

10.  Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.

Authors:  William L Kelley; Ambre Jousselin; Christine Barras; Emmanuelle Lelong; Adriana Renzoni
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.